AMLX: Guggenheim Raises Target
Guggenheim analyst Seamus Fernandez maintains Buy on Amylyx Pharmaceuticals and raises the price target to $40
Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ: AMLX ) with a Buy and raises the price target from $30 to $40.